Risk factors
Keros Therapeutics (KROS) risk factors
Item 1A of every Keros Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors76 risks6 new8 dropped16 reworded
Keros Therapeutics restructured with a 45% workforce reduction and initiated a $375 million capital return strategy. The company relies heavily on the development and commercialization of drug candidates like elritercept and rinvatercept.
Filed Mar 04, 2026 - FY2024 10-K risk factors78 risks
Keros Therapeutics faces high risks typical of clinical-stage biopharmaceutical companies, focusing heavily on financing needs, regulatory hurdles, intense competition, and intellectual property protection.
Filed Feb 26, 2025